We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA Outlines Vaccine Measures for Pharmacovigilance
EMEA Outlines Vaccine Measures for Pharmacovigilance
September 17, 2009
Drugmakers marketing vaccines to prevent infectious diseases should investigate identified safety concerns before applying for a marketing authorization and address the concerns in a risk management plan, the European Medicines Agency (EMEA) says. Includes the full text of EMEA Guideline on Pharmacovigilance
For Vaccines.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor